Building Fit-for-Purpose Oncology Real-World Evidence in Japan
Earn a Certificate of Live Attendance
AI Webinar Explorer available after event
About this webinar
Japan is one of the world’s largest oncology markets and an increasingly important part of global real-world evidence (RWE) strategies. Yet oncology RWE in Japan has developed differently than in the US and Europe, shaped by distinct data sources, care delivery models and evolving sponsor needs across clinical development, medical affairs and evidence planning.
As sponsors expand their global evidence programs, Japanese data has become central to a representative RWE strategy. In this panel discussion, experts from across the industry will discuss how global biopharma teams can succeed with Japan RWE programs. Topics will include:
- How oncology RWE adoption in Japan compares to other major markets and what’s driving recent momentum
- What distinguishes fit-for-purpose Japanese EHR-derived real-world data (RWD) from claims or registry datasets
- Industry perspectives on data quality, completeness and relevance for real-world research
- Practical considerations for global teams partnering with local experts on Japan evidence strategies
Register for this webinar to learn how RWE can support fit-for-purpose oncology evidence strategies in Japan.
Who should attend
- Real-World Evidence / Real-World Data
- Health Economics and Outcomes Research (HEOR)
- Medical Affairs
- Market Access
- Clinical Development
- Commercial
- Regulatory Affairs
- Biostatistics / Epidemiology
What you will learn
- The current state of oncology RWE in Japan and how it fits into global evidence strategies
- What clinical and data leaders prioritize when building and evaluating Japanese real-world datasets
- Practical lessons from collaborative oncology RWD work in Japan
- Key considerations for global teams exploring or expanding Japan evidence programs
Featured Speakers
(Moderator) Eri Tajima
Eri Tajima is Country Lead at Flatiron Health Japan, where she leads the Japan office and drives business development and partnership strategy with cancer hospitals, biopharma companies and regulatory stakeholders across the region. She works closely with cross-functional teams to expand Flatiron’s real-world data offerings in Japan and strengthen relationships with hospital and pharmaceutical partners on oncology research collaborations. Prior to joining Flatiron, she was at Accenture advising pharmaceutical clients in Japan on real-world data and digital strategy. Eri holds undergraduate and graduate degrees in Pharmaceutical Science from the University of Tokyo and is fluent in both Japanese and English.
Hideaki Bando
Hideaki Bando, MD, PhD, is a medical oncologist in the Department of Gastrointestinal Oncology and Head of the Division of Drug Development Promotion at the National Cancer Center Hospital East, Japan. His clinical and research interests include gastrointestinal oncology, precision medicine, cancer genomics, circulating tumor DNA, and the generation and application of real-world evidence. He has led and contributed to nationwide multicenter studies and international collaborations aimed at advancing biomarker-driven drug development and improving the integration of genomic and clinical data in oncology.
Yasushi Goto
Yasushi Goto, MD, PhD, is Chief of the Department of Thoracic Oncology at the National Cancer Center Hospital, Tokyo, and a lecturer at the University of Tokyo, where he earned his MD and PhD. His work focuses on lung cancer, particularly precision oncology, biomarker-driven therapies, and immunotherapy. He led a phase III trial on the optimal duration of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer and has authored more than 240 peer-reviewed publications. He is a Board Member of the Japanese Society of Medical Oncology and an Editor of the Japanese Journal of Clinical Oncology.
Dina Oksen
Dina Oksen is an epidemiologist with more than a decade of experience in the pharmaceutical industry, leading evidence generation strategies to support drug development programs, regulatory interactions, product launches, and life cycle management. She currently serves as Asia R&D Real World Data & Analytics Lead at GSK, leading expert teams responsible for generating regulatory-grade RWE and advanced analytics. Previously, Dina held global leadership roles in oncology epidemiology and RWE at Merck KGaA and Bayer. Presently she is focused on advancing the use of Asian real-world data and advanced analytics to address local and global evidence needs.
Partner for this event
Flatiron Health
At Flatiron Health, we combine AI-powered technology, deep clinical expertise, and real-world oncology data to help our partners navigate cancer care and research with greater clarity and speed. Our global oncology engine is built on one of the world’s largest oncology datasets across the US, UK, Germany, and Japan, alongside point of care technology used by community oncologists across the US.
We help thousands of providers and life science organizations to generate deeper insights, move faster, and improve outcomes for people living with cancer.